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medications for 1Q98. Patients and providers were sent
educational material relating to identified risk and behav-
ioral and pharmacologic treatment options for the pre-
vention/management of CAD. The primary endpoint was
increased use of antilipemics and/or estrogen.
RESULTS: Of 60,241 patients, 3515 were identified with
at least one risk factor (at-risk CAD). Employer A had an
at-risk CAD prevalence rate of 9% (90.5% female/mean
age 60; men 55 years). Employer B had an at-risk preva-
lence rate of 16% (69.2% female/mean age 69; men 65
years). The predominant risk factor was postmenopausal
status (59%), followed by diabetes (33%) and nitrate
use (7.2%). Two or more risk factors were present in
12.3% and 13.8% of groups A and B, respectively. Post-
intervention, group A had a 9.2% increase in the utiliza-
tion of lipid-altering medications (55 on HMG-CoA in-
hibitors and 71 on estrogen). Group B witnessed an in-
crease of 5.6% (89 on HMGs and 32 on estrogen). Of
patients with three risk factors, group A had a 42% initi-
ation rate while group B a 33% rate.
CONCLUSIONS: An educational campaign toward pa-
tients and prescribers resulted in meaningful increases in
lipid-altering medication use. Patients with assumed
highest risk had the greatest increase in utilization. En-
hanced education is a cost-efficient method for improv-
ing utilization.
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OBJECTIVES: To assess clinical outcomes including 1)
National Cholesterol Education Panel (NCEP) Adult Treat-
ment Panel II goal attainment, and 2) percent low-density
lipoprotein cholesterol (LDL-C) reduction in a patient pop-
ulation treated with antihyperlipidemic medications.
METHODS: Medical charts were utilized to collect de-
mographic and clinical data from a random sample of
patients receiving lipid-lowering therapy at two managed
care sites in the southeastern United States from April
1997 to July 1998. Stratified univariate statistics and chi-
square tests were performed.
RESULTS: Data from 531 patients were analyzed, 287
(54%) of whom were women. The mean age at baseline
was 63.7 years. Drug utilization was as follows: 123
(22.8%) were being treated with atorvastatin, 69 (12.8%)
with fluvastatin, 42 (7.8%) with lovastatin, 158 (29.3%)
with pravastatin, 129 (23.9%) with simvastatin, and 10
(2%) with other agents. Due to small sample size, only
mean LDL-C reductions for each drug are presented. Mean
LDL-C reduction among patients receiving atorvastatin, flu-
vastatin, lovastatin, pravastatin, and simvastatin, respec-
tively, was 25.4%, 22.9%, 11.1%, 22.1%, and 26.2%. The
corresponding percentages of patients who met their NCEP
treatment targets were 57.3%, 50.8%, 34.2%, 50.7%, and
48%, respectively. The number of patients overall who met
their respective NCEP goals was 265 (50%).
CONCLUSIONS: Most agents showed similar activity
with regard to NCEP goal attainment. Further work will
be required to determine whether the observed similari-
ties in NCEP goal attainment will be reflected in other
outcome measures.
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OBJECTIVES: To estimate the cost per ischemic event
(death, nonfatal MI, and/or subsequent revasculariza-
tion) avoided over 6 months and to estimate the precision
of the cost-effectiveness ratio (CER).
METHODS: The sampling frame consisted of patients
undergoing a percutaneous revascularization procedure
at the University of Maryland Medical System to treat a
high-risk coronary lesion according to the American Col-
lege of Cardiology/American Heart Association morphol-
ogy classification system. Sixty-two patients treated with
abciximab were matched with 62 patients who were not
based on gender, diabetes, hyperlipidemia, and coronary
stenting. Three statistical methods were used to estimate
the precision of the CER: Taylor series; Fieller’s Theo-
rem; and confidence ellipsoids.
RESULTS: Abciximab-treated patients experienced a
41% reduction in the rate of ischemic events at 6 months
(16.1% versus 27.4%, p  0.128). The mean total cost of
inpatient treatment for abciximab-treated patients was
about $2460 higher than for patients not treated with ab-
ciximab. The point estimate for the CER was $21,789 per
ischemic event avoided at 6 months. Overall, confidence
intervals were relatively wide due to the non-significant
difference in the rate of ischemic events. Using the Taylor
series, the 90% CI ranged from $2097 to $41,480. A
90% CI could not be calculated using Fieller’s theorem.
However, the 80% CI ranged from $10,497 to $91,679.
Confidence ellipses provide an intuitive approach for vi-
sualizing the variability of differences in costs and effects
simultaneously.
CONCLUSIONS: Although institution-specific analyses
often lack power for hypothesis testing, the use of statis-
tical methods can provide decision-makers with a range
of CERs that are consistent with the data collected.
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